Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the …
GJ Brewer, F Askari, MT Lorincz, M Carlson… - Archives of …, 2006 - jamanetwork.com
Objective To compare tetrathiomolybdate and trientine in treating patients with the
neurologic presentation of Wilson disease for the frequency of neurologic worsening,
adverse effects, and degree of neurologic recovery. Design A randomized, double-blind,
controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease.
Patients either received 500 mg of trientine hydrochloride 2 times per day or 20 mg of
tetrathiomolybdate 3 times per day with meals and 20 mg 3 times per day between meals for …
neurologic presentation of Wilson disease for the frequency of neurologic worsening,
adverse effects, and degree of neurologic recovery. Design A randomized, double-blind,
controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease.
Patients either received 500 mg of trientine hydrochloride 2 times per day or 20 mg of
tetrathiomolybdate 3 times per day with meals and 20 mg 3 times per day between meals for …